Invent Medic to present the company at Swedish investor event on January 27
Invent Medic announces that CEO Karin Bryder will present the company at the Swedish investor event Aktiedagen i Lund on January 27, 2021 at 9.15 CET. The event can be viewed live or on demand via Aktiespararna’s YouTube channel or via aktiespararna.se.
Invent Medic’s company presentation at Aktiedagen i Lund is a part of an extended focus on IR communication activities in preparation for and during the exercise period of TO 1 series warrants. These warrants were distributed to all participants in Invent Medic’s preferential rights issue in February 2020, and each warrant grants the right to subscribe for one share at the price 6.75 SEK during February 25–March 18, 2021.
These IR communication activities will highlight Invent Medic in Q1 2021 via the following:
- Continued publication of the company’s appreciated newsletter in collaboration with the IR communication firm Honeybadger.
- Initiation of Invent Medic news coverage on Biostock.se, including the publication of a series of articles on the company. The first article can be found here: https://www.biostock.se/en/invent-medic-wants-to-improve-life-for-women-with-stress-urinary-incontinence/
- CEO interview with Karin Bryder on Biostock.se in late February 2021. The publication of the presentation will be followed by a live chat session where questions can be asked and will be answered live.
Invent Medic’s increased amount of IR communication activities in Q1 2021 will continue also going forward in 2021, with news coverage on Biostock.se, digital CEO presentations/comments in connection with selected newsletters and press releases, participation at more investor events and extended ongoing digital presence via social media.
For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com
About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.